Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials

Carfilzomib is a selective proteasome inhibitor approved for the treatment of relapsed and/or refractory multiple myeloma (RRMM). It has significantly improved outcomes, including overall survival (OS), and shown superiority vs standard treatment with lenalidomide plus dexamethasone and bortezomib p...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood Adv
Prif Awduron: Chari, Ajai, Stewart, A. Keith, Russell, Stuart D., Moreau, Philippe, Herrmann, Joerg, Banchs, Jose, Hajek, Roman, Groarke, John, Lyon, Alexander R., Batty, George N., Ro, Sunhee, Huang, Mei, Iskander, Karim S., Lenihan, Daniel
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2018
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6039655/
https://ncbi.nlm.nih.gov/pubmed/29991494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017015545
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg